Short-term anabolic treatment for osteoporosis in postmenopausal women
Limited-duration anabolic therapy in postmenopausal osteoporosis
This study is looking at a new way to help women who have postmenopausal osteoporosis by using a short-term treatment with a medication called romosozumab to build bone, followed by another medicine to help prevent bone loss, to see if this combination can lower the chance of fractures while keeping heart health in mind.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10703413 on NIH RePORTER |
What this research studies
This research investigates a new approach to treating postmenopausal osteoporosis by using a limited-duration therapy with the medication romosozumab, which stimulates bone formation. The study aims to determine if a shorter course of this medication, followed by another drug that inhibits bone resorption, can effectively reduce the risk of fractures. By focusing on the timing and combination of these treatments, the research seeks to improve patient outcomes while minimizing potential cardiovascular risks associated with longer-term use of romosozumab.
Who could benefit from this research
Good fit: Ideal candidates for this research are postmenopausal women at high risk for osteoporotic fractures.
Not a fit: Patients who are not postmenopausal or those without osteoporosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for preventing fractures in postmenopausal women with osteoporosis.
How similar studies have performed: Previous research has shown that similar approaches using romosozumab have been effective, but this specific combination therapy is novel.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Leder, Benjamin Z — Massachusetts General Hospital
- Study coordinator: Leder, Benjamin Z
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.